Search
encorafenib (Mektovi)
FDA approved June 2018
Indications:
- for use in combination with binimetinib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma
Dosage:
- 50-75 mg PO
Capsules: 50 mg. 75 mg
Adverse effects:
- palmoplantar erythrodysaesthesia syndrome
- myalgia
- arthralgia [3]
Mechanism of action:
- BRAF inhibitor
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=50922675
References
- RxNorm
- Wikipedia: Encorafenib
https://en.wikipedia.org/wiki/Encorafenib
- Dummer R, Ascierto PA, Gogas HJ et al
Encorafenib plus binimetinib versus vemurafenib or encorafenib
in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre,
open-label, randomised phase 3 trial.
Lancet Oncol. 2018 May;19(5):603-615.
PMID: 29573941
Component-of
binimetinib/encorafenib